460MO Preliminary Results from a Phase I Study Using the Bispecific, Human Epidermal Growth Factor 2 (Her2)-Targeting Antibody-Drug Conjugate (ADC) Zanidatamab Zovodotin (ZW49) in Solid Cancers
ANNALS OF ONCOLOGY(2022)
Key words
HER2
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined